Servier completed its acquisition of Day One Biopharmaceuticals and its buyout of Edgewise Therapeutics’ neuromuscular business is expected to close later this year. At the BIO International Convention, Servier’s top business development executive explained the rationale for these deals and how they fit the company’s overall strategy. The post Servier Executive: ‘We Are Not Looking…
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.
I was a little surprised that in the days of limitless content, AI, and all types of medical information being online a company could raise $15m to create a platform where actual doctors could answer specific questions that patients might have. Vikram Bhaskaran, the CEO is ex Pinterest and knows the consumer world well. Rohan…
[Sponsored] Unlike inpatient recovery, which requires you to live at a facility full-time, outpatient care allows you to continue working and maintain important relationships while getting necessary care. The post Your Guide to Outpatient Addiction Treatment: Top Choices in Sacramento and Beyond appeared first on MedCity News.
Teal Health raised $10 million in seed funding, taking its total funding to $23 million. The company has submitted an application to the FDA for its at-home cervical cancer screening kit, which seeks to give patients an alternative to the in-office pap smear. The post Meet the Company Developing an At-Home Test to Replace the…
Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer appeared first…
Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children. The post Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma…
In recent years, states across the Mountain West have passed laws that limit doctors from providing transgender children with certain kinds of gender-affirming care, from prohibitions on surgery to bans on puberty blockers and hormones. Colorado families say their state was a haven for those health services for a long time, but following executive orders…
One day after the murder of UnitedHealthcare’s CEO, police are searching for the shooter
Premature claims about Tylenol and autism put politics ahead of science and risk eroding the public trust essential to health. The post Public Health Cannot Survive on Soundbites appeared first on MedCity News.